{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:28:19Z","timestamp":1793975299135,"version":"4.8.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bbrep.2026.102817","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:08:13Z","timestamp":1790413693000},"page":"102817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["siRNA therapeutics for metabolic dysfunction-associated Steatohepatitis: Targets, delivery, clinical evidence, and translational challenges"],"prefix":"10.1016","volume":"48","author":[{"given":"Yanan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunyan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbrep.2026.102817_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103910","article-title":"NAFLD and NASH: etiology, targets and emerging therapies","volume":"29","author":"Wei","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.bbrep.2026.102817_bib2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102817_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102817_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann. Hepatol."},{"issue":"6","key":"10.1016\/j.bbrep.2026.102817_bib5","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bbrep.2026.102817_bib6","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1016\/j.bbrep.2026.102817_bib7","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"issue":"10","key":"10.1016\/j.bbrep.2026.102817_bib8","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102817_bib9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.plipres.2012.10.004","article-title":"Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease","volume":"52","author":"Leamy","year":"2013","journal-title":"Prog. Lipid Res."},{"issue":"9","key":"10.1016\/j.bbrep.2026.102817_bib10","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1074\/jbc.M113.541110","article-title":"Sterol regulatory element-binding protein-1 (SREBP-1) is required to regulate glycogen synthesis and gluconeogenic gene expression in mouse liver","volume":"289","author":"Ruiz","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bbrep.2026.102817_bib11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2337\/db14-0582","article-title":"Regulation of AMPK activation by CD36 links fatty acid uptake to \u03b2-oxidation","volume":"64","author":"Samovski","year":"2015","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.bbrep.2026.102817_bib12","doi-asserted-by":"crossref","first-page":"G341","DOI":"10.1152\/ajpgi.00163.2022","article-title":"ATF4-mediated CD36 upregulation contributes to palmitate-induced lipotoxicity in hepatocytes","volume":"324","author":"Griffiths","year":"2023","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102817_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12944-018-0790-9","article-title":"Long-chain fatty acid activates hepatocytes through CD36 mediated oxidative stress","volume":"17","author":"Liu","year":"2018","journal-title":"Lipids Health Dis."},{"issue":"12","key":"10.1016\/j.bbrep.2026.102817_bib14","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/14728222.2021.2018418","article-title":"PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date","volume":"25","author":"Cherubini","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"issue":"4","key":"10.1016\/j.bbrep.2026.102817_bib15","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2022.11.025","article-title":"A phase I\/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis","volume":"78","author":"Mak","year":"2023","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.bbrep.2026.102817_bib16","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bbrep.2026.102817_bib17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.bbrep.2026.102817_bib18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.bbrep.2026.102817_bib19","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102817_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.bbrep.2026.102817_bib21","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102817_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1172\/JCI88881","article-title":"Liver inflammation and fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.bbrep.2026.102817_bib23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrep.2026.102817_bib24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2022.01.038","article-title":"Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis","volume":"343","author":"Zhou","year":"2022","journal-title":"J Control Release"},{"issue":"8","key":"10.1016\/j.bbrep.2026.102817_bib25","doi-asserted-by":"crossref","first-page":"10492","DOI":"10.1021\/acsami.2c22579","article-title":"Liver-targeted delivery of small interfering RNA of C\u2013C chemokine receptor 2 with tetrahedral framework nucleic acid attenuates liver cirrhosis","volume":"15","author":"Tian","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"599","key":"10.1016\/j.bbrep.2026.102817_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe1692","article-title":"Hepatocyte TLR4 triggers inter-hepatocyte Jagged1\/Notch signaling to determine NASH-induced fibrosis","volume":"13","author":"Yu","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102817_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.04.003","article-title":"Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized Study","volume":"22","author":"Anstee","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.bbrep.2026.102817_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166731","article-title":"Hepatocyte-specific CCAAT\/enhancer binding protein \u03b1 restricts liver fibrosis progression","volume":"134","author":"Yan","year":"2024","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.bbrep.2026.102817_bib29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jhep.2024.04.009","article-title":"Targeting EFHD2 inhibits interferon-\u03b3 signaling and ameliorates non-alcoholic steatohepatitis","volume":"81","author":"Fu","year":"2024","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.bbrep.2026.102817_bib30","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1136\/gutjnl-2023-331447","article-title":"Neutrophil extracellular traps activate hepatic stellate cells and monocytes via NLRP3 sensing in alcohol-induced acceleration of MASH fibrosis","volume":"73","author":"Babuta","year":"2024","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102817_bib31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","article-title":"Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH)","volume":"7","author":"Xu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.bbrep.2026.102817_bib32","first-page":"1","article-title":"Hepatic stellate cells in liver fibrosis and siRNA-Based therapy","volume":"172","author":"Omar","year":"2016"},{"key":"10.1016\/j.bbrep.2026.102817_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101165","article-title":"Hepatocyte-targeted siTAZ therapy lowers liver fibrosis in NASH diet-fed chimeric mice with hepatocyte-humanized livers","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"3","key":"10.1016\/j.bbrep.2026.102817_bib34","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.bbrc.2011.05.023","article-title":"The antifibrotic effects of TGF-\u03b21 siRNA on hepatic fibrosis in rats","volume":"409","author":"Lang","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"15","key":"10.1016\/j.bbrep.2026.102817_bib35","doi-asserted-by":"crossref","first-page":"14852","DOI":"10.1021\/acsnano.3c03217","article-title":"Nanoparticle-mediated RNA therapy attenuates nonalcoholic steatohepatitis and related fibrosis by targeting activated hepatic stellate cells","volume":"17","author":"Zhang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbrep.2026.102817_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122134","article-title":"Retinol-binding protein-hijacking nanopolyplex delivering siRNA to cytoplasm of hepatic stellate cell for liver fibrosis alleviation","volume":"299","author":"Huang","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbrep.2026.102817_bib37","series-title":"Safety and Effectiveness of BMS-986263 in Adults with Compensated Cirrhosis from Nonalcoholic Steatohepatitis","year":"2024"},{"issue":"4","key":"10.1016\/j.bbrep.2026.102817_bib38","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bbrep.2026.102817_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155607","article-title":"Hepatic insulin receptor: new views on the mechanisms of liver disease","volume":"145","author":"Lee","year":"2023","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.bbrep.2026.102817_bib40","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.bbrep.2026.102817_bib41","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bbrep.2026.102817_bib42","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.soard.2018.12.002","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis","volume":"15","author":"Fakhry","year":"2019","journal-title":"Surg. Obes. Relat. Dis."},{"issue":"6","key":"10.1016\/j.bbrep.2026.102817_bib43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.bbrep.2026.102817_bib44","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrep.2026.102817_bib45","series-title":"FDA Approves Treatment for Serious Liver Disease Known as \u2018MASH\u2019","year":"2025"},{"key":"10.1016\/j.bbrep.2026.102817_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106786","article-title":"Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)","volume":"192","author":"Qiu","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102817_bib47","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.bbrep.2026.102817_bib48","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with Nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann. Intern. Med."},{"issue":"9972","key":"10.1016\/j.bbrep.2026.102817_bib49","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.bbrep.2026.102817_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2021.07.020","article-title":"Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-Month interim analysis","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.bbrep.2026.102817_bib51","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR agonists for MASH therapy: lessons and perspectives from obeticholic acid","volume":"44","author":"Wang","year":"2024","journal-title":"Med. Res. Rev."},{"issue":"10215","key":"10.1016\/j.bbrep.2026.102817_bib52","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bbrep.2026.102817_bib53","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by Nonalcoholic steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102817_bib54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.bbrep.2026.102817_bib55","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1056\/NEJMc2402341","article-title":"Phase 1 trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD","volume":"391","author":"Fabbrini","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bbrep.2026.102817_bib56","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biotechadv.2019.04.012","article-title":"RNAi therapeutic and its innovative biotechnological evolution","volume":"37","author":"Weng","year":"2019","journal-title":"Biotechnol. Adv."},{"issue":"9","key":"10.1016\/j.bbrep.2026.102817_bib57","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102817_bib58","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nrc2966","article-title":"RNA interference in the clinic: challenges and future directions","volume":"11","author":"Pecot","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.bbrep.2026.102817_bib59","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","article-title":"RNAi-based drug design: considerations and future directions","volume":"23","author":"Tang","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"21","key":"10.1016\/j.bbrep.2026.102817_bib60","doi-asserted-by":"crossref","first-page":"9329","DOI":"10.1093\/nar\/gkr586","article-title":"Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L","volume":"39","author":"Anderson","year":"2011","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102817_bib61","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","article-title":"Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity","volume":"9","author":"Janas","year":"2018","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bbrep.2026.102817_bib62","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nbt1081","article-title":"Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA","volume":"23","author":"Judge","year":"2005","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102817_bib63","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2024.12.046","article-title":"AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials","volume":"83","author":"Armisen","year":"2025","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.bbrep.2026.102817_bib64","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbrep.2026.102817_bib65","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bbrep.2026.102817_bib66","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol."},{"issue":"5","key":"10.1016\/j.bbrep.2026.102817_bib79","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/jcph.6174","article-title":"Preclinical and clinical pharmacokinetics of JNJ-75220795, an siRNA therapeutic targeting PNPLA3, for Metabolic dysfunction-associated steatohepatitis","volume":"65","author":"Jeon","year":"2025","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.bbrep.2026.102817_bib80","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jhep.2025.05.031","article-title":"Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis","volume":"83","author":"Sanyal","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrep.2026.102817_bib81","series-title":"A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients with Nonalcoholic Steatohepatitis (NASH)","year":"2024"},{"key":"10.1016\/j.bbrep.2026.102817_bib83","year":"2025"},{"issue":"4","key":"10.1016\/j.bbrep.2026.102817_bib82","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/hep.32181","article-title":"BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial","volume":"75","author":"Lawitz","year":"2022","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.bbrep.2026.102817_bib84","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1016\/j.apsb.2022.02.003","article-title":"Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease","volume":"12","author":"Tong","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"5","key":"10.1016\/j.bbrep.2026.102817_bib85","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1080\/10715762.2019.1608982","article-title":"Evaluation of the therapeutic potential effect of Fas receptor gene knockdown in experimental model of non-alcoholic steatohepatitis","volume":"53","author":"Savari","year":"2019","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.bbrep.2026.102817_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125291","article-title":"Rubicon siRNA-encapsulated liver-targeting nanoliposome is a promising therapeutic for non-alcoholic fatty liver disease","volume":"672","author":"Zhang","year":"2025","journal-title":"Int J Pharm"},{"issue":"12","key":"10.1016\/j.bbrep.2026.102817_bib67","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/gt.2011.56","article-title":"Special delivery: targeted therapy with small RNAs","volume":"18","author":"Peer","year":"2011","journal-title":"Gene Ther."},{"issue":"2","key":"10.1016\/j.bbrep.2026.102817_bib68","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102817_bib69","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbrep.2026.102817_bib70","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jconrel.2024.07.011","article-title":"Lipid nanoparticle-mediated hepatocyte delivery of siRNA and silibinin in metabolic dysfunction-associated steatotic liver disease","volume":"373","author":"Lyu","year":"2024","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bbrep.2026.102817_bib71","series-title":"Drug Trials Snapshots: REDEMPLO","year":"2025"},{"issue":"6","key":"10.1016\/j.bbrep.2026.102817_bib72","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1021\/acsnano.3c06107","article-title":"Antioxidative hyaluronic acid\u2013bilirubin nanomedicine targeting activated hepatic stellate cells for anti-hepatic-fibrosis therapy","volume":"18","author":"Shinn","year":"2024","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102817_bib73","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1021\/acs.molpharmaceut.7b00709","article-title":"pPB peptide-mediated siRNA-Loaded stable nucleic acid lipid nanoparticles on targeting therapy of hepatic fibrosis","volume":"15","author":"Jia","year":"2018","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102817_bib74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41467-022-35637-z","article-title":"Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis","volume":"14","author":"Han","year":"2023","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.bbrep.2026.102817_bib75","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"17","key":"10.1016\/j.bbrep.2026.102817_bib76","article-title":"Restoration of Sinusoid fenestrae followed by targeted nanoassembly delivery of an anti-fibrotic agent improves treatment efficacy in liver fibrosis","volume":"35","author":"Li","year":"2023","journal-title":"Adv Mater"},{"issue":"2","key":"10.1016\/j.bbrep.2026.102817_bib77","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1089\/nat.2020.0879","article-title":"Considerations of the Japanese research working group for the ICH S6 & related issues regarding nonclinical safety assessments of oligonucleotide therapeutics: Comparison with those of biopharmaceuticals","volume":"31","author":"Hirabayashi","year":"2021","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.bbrep.2026.102817_bib78","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154\u2013155","author":"Kozma","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"10","key":"10.1016\/j.bbrep.2026.102817_bib87","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41575-023-00796-x","article-title":"Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach","volume":"20","author":"Brennan","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrep.2026.102817_bib88","series-title":"Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics: Guidance for Industry","year":"2024"},{"issue":"2","key":"10.1016\/j.bbrep.2026.102817_bib89","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1517\/17425247.2012.642363","article-title":"Challenges in the pharmaceutical development of lipid-based short interfering ribonucleic acid therapeutics","volume":"9","author":"Gindy","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.bbrep.2026.102817_bib90","series-title":"Noncirrhotic Nonalcoholic Steatohepatitis with Liver Fibrosis: Developing Drugs for Treatment\u2014Draft Guidance for Industry","year":"2018"},{"issue":"6","key":"10.1016\/j.bbrep.2026.102817_bib91","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","author":"Davison","year":"2020","journal-title":"J. Hepatol."}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580826003778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580826003778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:08:26Z","timestamp":1793974106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580826003778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":91,"alternative-id":["S2405580826003778"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2026.102817","relation":{},"ISSN":["2405-5808"],"issn-type":[{"value":"2405-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"siRNA therapeutics for metabolic dysfunction-associated Steatohepatitis: Targets, delivery, clinical evidence, and translational challenges","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2026.102817","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102817"}}